Benicar Sales Aid Draws FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency objects to superiority and efficacy claims for the Forest/Sankyo angiotension II receptor blocker based on misleading comparisons and inadequate studies.
You may also be interested in...
Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says
The impact of media attention on the adult suicide issue will be “hard to predict,” President & COO Goodman says. Forest expects FDA action on a Namenda supplemental NDA for mild-to-moderate Alzheimer’s in the next few weeks.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.